Survival outcomes of patients with head and neck squamous cell cancer with hepatitis B virus infection: An analysis from an endemic tertiary center
[3];
[4];
[5]
- Division of Hematology/Medical Oncology, Department of Medicine Taichung Veterans General Hospital Taichung Taiwan
- Division of Hematology/Medical Oncology, Department of Medicine Taichung Veterans General Hospital Taichung Taiwan, Department of Post‐Baccalaureate Medicine, College of Medicine National Chung Hsing University Taipei Taiwan
- School of Medicine National Yang Ming Chiao Tung University Taichung Taiwan, School of Speech Language Pathology &, Audiology Chung Shan Medical University Taichung Taiwan, Department of Audiology and Speech‐Language Pathology Asia University Taichung Taiwan, Department of Otolaryngology‐Head &, Neck Surgery Taichung Veterans General Hospital Taichung Taiwan
- Division of Hematology/Medical Oncology, Department of Medicine Taichung Veterans General Hospital Taichung Taiwan, Department of Post‐Baccalaureate Medicine, College of Medicine National Chung Hsing University Taipei Taiwan, Department of Life Science Tunghai University Taichung Taiwan, School of Medicine Chung Shan Medical University Taichung Taiwan
- Division of Hematology/Medical Oncology, Department of Medicine Taichung Veterans General Hospital Taichung Taiwan, Department of Post‐Baccalaureate Medicine, College of Medicine National Chung Hsing University Taipei Taiwan, Graduate Institute of Biomedical Sciences China Medical University Taichung Taiwan
Abstract Background Hepatitis B virus (HBV) affects the occurrence and survival outcome of various malignant disorders. The study aimed to evaluate the survival outcome of head and neck squamous cell cancer (HNSCC) patients with or without HBV infection. Methods This study included patients with HNSCC who visited Taichung Veterans General Hospital from 2007 to 2015. HBV infection was defined by hepatitis B surface antigen (HBsAg) seropositivity. By propensity score matching, we compared survival outcomes, including progression‐free survival (PFS) and overall survival (OS), among patients with or without HBV infection. Results The prevalence of HBV infection in our cohort was 12.3%. Among the 1,015 patients included in the matched analysis, a higher risk of baseline liver cirrhosis (11.3% vs. 3.4%, p < 0.001) and initial hepatic dysfunction (10.8% vs. 5.4%, p = 0.005) rates were observed than those without HBV infection at baseline. The 5‐year OS was 43.1% and 53.2% ( p < 0.001) and the 5‐year PFS was 37.4% and 42.3% ( p = 0.007) in patients with and without HBV infection, respectively. The incidence of subsequent hepatic dysfunction showed no difference between patients with and without HBV infection (29.6% vs. 26.8%, p = 0.439). Conclusions Patients with HNSCC and HBV infection were younger and had a higher risk of cirrhosis compared to those without HBV infection. Moreover, HBV infection significantly influenced the OS and PFS outcomes but not subsequent hepatic dysfunction in patients with HNSCC.
- Sponsoring Organization:
- USDOE
- OSTI ID:
- 1899803
- Alternate ID(s):
- OSTI ID: 1899804
- Journal Information:
- Cancer medicine, Journal Name: Cancer medicine Vol. 12 Journal Issue: 6; ISSN 2045-7634
- Publisher:
- Wiley Blackwell (John Wiley & Sons)Copyright Statement
- Country of Publication:
- United Kingdom
- Language:
- English
Similar Records
Usefulness of Interim FDG-PET After Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Sequential Induction Chemotherapy Followed by Concurrent Chemoradiotherapy
Outcomes of Locoregional Tumor Therapy for Patients with Hepatocellular Carcinoma and Transjugular Intrahepatic Portosystemic Shunts